Brief: Ocuphire Pharma Announces Submission Of NDA To FDA For Nyxol Eye Drops
06/12/2022 11:59
Dec 6 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE PHARMA ANNOUNCES SUBMISSION OF NEW DRUG
APPLICATION TO
FDA FOR NYXOL® EYE DROPS FOR REVERSAL OF MYDRIASIS
* OCUPHIRE PHARMA - COMBINED WITH PREVIOUS REPORTED CASH
BALANCE
OF $13.9 MILLION AT SEPT 30, BELIEVES IT HAS SUFFICIENT CAPITAL
TO FUND OPERATIONS INTO 2025
Source text for Eikon: ID:nGNX3Z6C2k
Further company coverage: OCUP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data